La thérapie familiale en francophonie (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Patient adherence to aromatase inhibitor treatment in the adjuvant setting

Identifieur interne : 000243 ( Pmc/Corpus ); précédent : 000242; suivant : 000244

Patient adherence to aromatase inhibitor treatment in the adjuvant setting

Auteurs : S. Verma ; Y. Madarnas ; S. Sehdev ; G. Martin ; J. Bajcar

Source :

RBID : PMC:3119895

Abstract

Improvements in adjuvant systemic therapy and detection of early disease have resulted in a decline of breast cancer death rates across all patient age groups in Canada. Non-adherence to adjuvant hormonal therapy in the setting of early breast cancer may significantly affect patient outcome. Factors associated with medication adherence are complex and may be patient-related, therapy-related, and health care provider–related. To date, there is a gap in the literature concerning a comprehensive understanding of factors related to medication adherence with anti-estrogen therapy in the adjuvant setting. The literature suggests that strategies for improving adherence should focus on education of patients, assessment of the ability of patients to understand their disease and related recurrence factors, and facilitation of adherence by patients by providing adequate support and strategies for good self-management. However, more research is needed to better understand how health care providers can support women with breast cancer on oral therapy in the adjuvant setting.


Url:

Links to Exploration step

PMC:3119895

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Patient adherence to aromatase inhibitor treatment in the adjuvant setting</title>
<author>
<name sortKey="Verma, S" sort="Verma, S" uniqKey="Verma S" first="S." last="Verma">S. Verma</name>
<affiliation>
<nlm:aff id="af1-conc-18-s3">Division of Medical Oncology, Toronto–Sunnybrook Regional Cancer Centre, Sunnybrook and Women’s College Health Sciences Centre, Toronto, ON</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Madarnas, Y" sort="Madarnas, Y" uniqKey="Madarnas Y" first="Y." last="Madarnas">Y. Madarnas</name>
<affiliation>
<nlm:aff id="af2-conc-18-s3">Kingston Regional Cancer Centre, Kingston, ON</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Sehdev, S" sort="Sehdev, S" uniqKey="Sehdev S" first="S." last="Sehdev">S. Sehdev</name>
<affiliation>
<nlm:aff id="af3-conc-18-s3">The Oncology Group, William Osler Health Centre, Brampton, ON</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Martin, G" sort="Martin, G" uniqKey="Martin G" first="G." last="Martin">G. Martin</name>
<affiliation>
<nlm:aff id="af4-conc-18-s3">Department of Surgery, Centre hospitalier de l’Université de Montréal, Montréal, QC</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Bajcar, J" sort="Bajcar, J" uniqKey="Bajcar J" first="J." last="Bajcar">J. Bajcar</name>
<affiliation>
<nlm:aff id="af5-conc-18-s3">Department of Pharmacy, Sunnybrook Health Sciences Center, Toronto, ON</nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PMC</idno>
<idno type="pmid">21698059</idno>
<idno type="pmc">3119895</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3119895</idno>
<idno type="RBID">PMC:3119895</idno>
<date when="2011">2011</date>
<idno type="wicri:Area/Pmc/Corpus">000243</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000243</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a" type="main">Patient adherence to aromatase inhibitor treatment in the adjuvant setting</title>
<author>
<name sortKey="Verma, S" sort="Verma, S" uniqKey="Verma S" first="S." last="Verma">S. Verma</name>
<affiliation>
<nlm:aff id="af1-conc-18-s3">Division of Medical Oncology, Toronto–Sunnybrook Regional Cancer Centre, Sunnybrook and Women’s College Health Sciences Centre, Toronto, ON</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Madarnas, Y" sort="Madarnas, Y" uniqKey="Madarnas Y" first="Y." last="Madarnas">Y. Madarnas</name>
<affiliation>
<nlm:aff id="af2-conc-18-s3">Kingston Regional Cancer Centre, Kingston, ON</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Sehdev, S" sort="Sehdev, S" uniqKey="Sehdev S" first="S." last="Sehdev">S. Sehdev</name>
<affiliation>
<nlm:aff id="af3-conc-18-s3">The Oncology Group, William Osler Health Centre, Brampton, ON</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Martin, G" sort="Martin, G" uniqKey="Martin G" first="G." last="Martin">G. Martin</name>
<affiliation>
<nlm:aff id="af4-conc-18-s3">Department of Surgery, Centre hospitalier de l’Université de Montréal, Montréal, QC</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Bajcar, J" sort="Bajcar, J" uniqKey="Bajcar J" first="J." last="Bajcar">J. Bajcar</name>
<affiliation>
<nlm:aff id="af5-conc-18-s3">Department of Pharmacy, Sunnybrook Health Sciences Center, Toronto, ON</nlm:aff>
</affiliation>
</author>
</analytic>
<series>
<title level="j">Current Oncology</title>
<idno type="ISSN">1198-0052</idno>
<idno type="eISSN">1718-7729</idno>
<imprint>
<date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass></textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">
<p>Improvements in adjuvant systemic therapy and detection of early disease have resulted in a decline of breast cancer death rates across all patient age groups in Canada. Non-adherence to adjuvant hormonal therapy in the setting of early breast cancer may significantly affect patient outcome. Factors associated with medication adherence are complex and may be patient-related, therapy-related, and health care provider–related. To date, there is a gap in the literature concerning a comprehensive understanding of factors related to medication adherence with anti-estrogen therapy in the adjuvant setting. The literature suggests that strategies for improving adherence should focus on education of patients, assessment of the ability of patients to understand their disease and related recurrence factors, and facilitation of adherence by patients by providing adequate support and strategies for good self-management. However, more research is needed to better understand how health care providers can support women with breast cancer on oral therapy in the adjuvant setting.</p>
</div>
</front>
</TEI>
<pmc article-type="research-article">
<pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Curr Oncol</journal-id>
<journal-id journal-id-type="iso-abbrev">Curr Oncol</journal-id>
<journal-id journal-id-type="publisher-id">CO</journal-id>
<journal-title-group>
<journal-title>Current Oncology</journal-title>
</journal-title-group>
<issn pub-type="ppub">1198-0052</issn>
<issn pub-type="epub">1718-7729</issn>
<publisher>
<publisher-name>Multimed Inc.</publisher-name>
<publisher-loc>66 Martin St. Milton, ON, Canada L9T 2R2</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">21698059</article-id>
<article-id pub-id-type="pmc">3119895</article-id>
<article-id pub-id-type="publisher-id">conc-18-s3</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Medical Oncology</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Patient adherence to aromatase inhibitor treatment in the adjuvant setting</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Verma</surname>
<given-names>S.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="af1-conc-18-s3">*</xref>
<xref ref-type="corresp" rid="c1-conc-18-s3"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Madarnas</surname>
<given-names>Y.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="af2-conc-18-s3">
<sup></sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sehdev</surname>
<given-names>S.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="af3-conc-18-s3">
<sup></sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Martin</surname>
<given-names>G.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="af4-conc-18-s3">
<sup>§</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bajcar</surname>
<given-names>J.</given-names>
</name>
<degrees>MScPhm EdD</degrees>
<xref ref-type="aff" rid="af5-conc-18-s3">
<sup>||</sup>
</xref>
</contrib>
</contrib-group>
<aff id="af1-conc-18-s3">
<label>*</label>
Division of Medical Oncology, Toronto–Sunnybrook Regional Cancer Centre, Sunnybrook and Women’s College Health Sciences Centre, Toronto, ON</aff>
<aff id="af2-conc-18-s3">
<label></label>
Kingston Regional Cancer Centre, Kingston, ON</aff>
<aff id="af3-conc-18-s3">
<label></label>
The Oncology Group, William Osler Health Centre, Brampton, ON</aff>
<aff id="af4-conc-18-s3">
<label>§</label>
Department of Surgery, Centre hospitalier de l’Université de Montréal, Montréal, QC</aff>
<aff id="af5-conc-18-s3">
<label>||</label>
Department of Pharmacy, Sunnybrook Health Sciences Center, Toronto, ON</aff>
<author-notes>
<corresp id="c1-conc-18-s3">Correspondence to: Sunil Verma, Sunnybrook Health Sciences Centre, T-Wing, 2nd Floor, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5. E-mail:
<email>sunil.verma@sunnybrook.ca</email>
</corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>5</month>
<year>2011</year>
</pub-date>
<volume>18</volume>
<issue>Suppl 1</issue>
<fpage>S3</fpage>
<lpage>S9</lpage>
<permissions>
<copyright-statement>2011 Multimed Inc.</copyright-statement>
<copyright-year>2011</copyright-year>
</permissions>
<abstract>
<p>Improvements in adjuvant systemic therapy and detection of early disease have resulted in a decline of breast cancer death rates across all patient age groups in Canada. Non-adherence to adjuvant hormonal therapy in the setting of early breast cancer may significantly affect patient outcome. Factors associated with medication adherence are complex and may be patient-related, therapy-related, and health care provider–related. To date, there is a gap in the literature concerning a comprehensive understanding of factors related to medication adherence with anti-estrogen therapy in the adjuvant setting. The literature suggests that strategies for improving adherence should focus on education of patients, assessment of the ability of patients to understand their disease and related recurrence factors, and facilitation of adherence by patients by providing adequate support and strategies for good self-management. However, more research is needed to better understand how health care providers can support women with breast cancer on oral therapy in the adjuvant setting.</p>
</abstract>
<kwd-group>
<kwd>Adherence</kwd>
<kwd>hormone receptor–positive breast cancer</kwd>
<kwd>adjuvant hormonal therapy</kwd>
<kwd>aromatase inhibitors</kwd>
<kwd>tamoxifen</kwd>
</kwd-group>
</article-meta>
</front>
</pmc>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Psychologie/corpus/TherFamFrancoV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000243 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Psychologie
   |area=    TherFamFrancoV1
   |flux=    Pmc
   |étape=   Corpus
   |type=    RBID
   |clé=     PMC:3119895
   |texte=   Patient adherence to aromatase inhibitor treatment in the adjuvant setting
}}

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Tue May 16 11:23:40 2017. Site generation: Thu Jul 20 16:14:43 2017